Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
June 9, 2020
Assignee:
Vactech 0y
Inventors:
Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg